IAP antagonists induce anti-tumor immunity in multiple myeloma

Marta Chesi, Noweeda N. Mirza, Victoria M. Garbitt, Meaghen E. Sharik, Amylou Dueck, Yan Asmann, Ilseyar Akhmetzyanova, Heidi E. Kosiorek, Arianna Calcinotto, Daniel L. Riggs, Niamh Keane, Gregory J. Ahmann, Kevin M. Morrison, Rafael Fonseca, Martha Lacy, David M Dingli, Shaji K Kumar, Sikander Ailawadhi, Angela Dispenzieri, Francis BuadiMorie Gertz, Craig B. Reeder, Yi Lin, Asher A Chanan Khan, Alexander Keith Stewart, David Fooksman, Peter Leif Bergsagel

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The cellular inhibitors of apoptosis (cIAP) 1 and 2 are amplified in about 3% of cancers and have been identified in multiple malignancies as being potential therapeutic targets as a result of their role in the evasion of apoptosis. Consequently, small-molecule IAP antagonists, such as LCL161, have entered clinical trials for their ability to induce tumor necrosis factor (TNF)-mediated apoptosis of cancer cells. However, cIAP1 and cIAP2 are recurrently homozygously deleted in multiple myeloma (MM), resulting in constitutive activation of the noncanonical nuclear factor (NF)-ΰ B pathway. To our surprise, we observed robust in vivo anti-myeloma activity of LCL161 in a transgenic myeloma mouse model and in patients with relapsed-refractory MM, where the addition of cyclophosphamide resulted in a median progression-free-survival of 10 months. This effect was not a result of direct induction of tumor cell death, but rather of upregulation of tumor-cell-autonomous type I interferon (IFN) signaling and a strong inflammatory response that resulted in the activation of macrophages and dendritic cells, leading to phagocytosis of tumor cells. Treatment of a MM mouse model with LCL161 established long-term anti-tumor protection and induced regression in a fraction of the mice. Notably, combination of LCL161 with the immune-checkpoint inhibitor anti-PD1 was curative in all of the treated mice.

Original languageEnglish (US)
Pages (from-to)1411-1420
Number of pages10
JournalNature Medicine
Volume22
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Multiple Myeloma
Tumors
Immunity
Apoptosis
Neoplasms
Chemical activation
Cells
Interferon Type I
Macrophages
Cell death
Refractory materials
Cyclophosphamide
Tumor Necrosis Factor-alpha
Cytophagocytosis
Macrophage Activation
Molecules
LCL161
Dendritic Cells
Transgenic Mice
Disease-Free Survival

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

IAP antagonists induce anti-tumor immunity in multiple myeloma. / Chesi, Marta; Mirza, Noweeda N.; Garbitt, Victoria M.; Sharik, Meaghen E.; Dueck, Amylou; Asmann, Yan; Akhmetzyanova, Ilseyar; Kosiorek, Heidi E.; Calcinotto, Arianna; Riggs, Daniel L.; Keane, Niamh; Ahmann, Gregory J.; Morrison, Kevin M.; Fonseca, Rafael; Lacy, Martha; Dingli, David M; Kumar, Shaji K; Ailawadhi, Sikander; Dispenzieri, Angela; Buadi, Francis; Gertz, Morie; Reeder, Craig B.; Lin, Yi; Chanan Khan, Asher A; Stewart, Alexander Keith; Fooksman, David; Bergsagel, Peter Leif.

In: Nature Medicine, Vol. 22, No. 12, 01.12.2016, p. 1411-1420.

Research output: Contribution to journalArticle

Chesi, M, Mirza, NN, Garbitt, VM, Sharik, ME, Dueck, A, Asmann, Y, Akhmetzyanova, I, Kosiorek, HE, Calcinotto, A, Riggs, DL, Keane, N, Ahmann, GJ, Morrison, KM, Fonseca, R, Lacy, M, Dingli, DM, Kumar, SK, Ailawadhi, S, Dispenzieri, A, Buadi, F, Gertz, M, Reeder, CB, Lin, Y, Chanan Khan, AA, Stewart, AK, Fooksman, D & Bergsagel, PL 2016, 'IAP antagonists induce anti-tumor immunity in multiple myeloma', Nature Medicine, vol. 22, no. 12, pp. 1411-1420. https://doi.org/10.1038/nm.4229
Chesi, Marta ; Mirza, Noweeda N. ; Garbitt, Victoria M. ; Sharik, Meaghen E. ; Dueck, Amylou ; Asmann, Yan ; Akhmetzyanova, Ilseyar ; Kosiorek, Heidi E. ; Calcinotto, Arianna ; Riggs, Daniel L. ; Keane, Niamh ; Ahmann, Gregory J. ; Morrison, Kevin M. ; Fonseca, Rafael ; Lacy, Martha ; Dingli, David M ; Kumar, Shaji K ; Ailawadhi, Sikander ; Dispenzieri, Angela ; Buadi, Francis ; Gertz, Morie ; Reeder, Craig B. ; Lin, Yi ; Chanan Khan, Asher A ; Stewart, Alexander Keith ; Fooksman, David ; Bergsagel, Peter Leif. / IAP antagonists induce anti-tumor immunity in multiple myeloma. In: Nature Medicine. 2016 ; Vol. 22, No. 12. pp. 1411-1420.
@article{15aec16587704ff5b5d8da9a95f9ad2c,
title = "IAP antagonists induce anti-tumor immunity in multiple myeloma",
abstract = "The cellular inhibitors of apoptosis (cIAP) 1 and 2 are amplified in about 3{\%} of cancers and have been identified in multiple malignancies as being potential therapeutic targets as a result of their role in the evasion of apoptosis. Consequently, small-molecule IAP antagonists, such as LCL161, have entered clinical trials for their ability to induce tumor necrosis factor (TNF)-mediated apoptosis of cancer cells. However, cIAP1 and cIAP2 are recurrently homozygously deleted in multiple myeloma (MM), resulting in constitutive activation of the noncanonical nuclear factor (NF)-{\^I}° B pathway. To our surprise, we observed robust in vivo anti-myeloma activity of LCL161 in a transgenic myeloma mouse model and in patients with relapsed-refractory MM, where the addition of cyclophosphamide resulted in a median progression-free-survival of 10 months. This effect was not a result of direct induction of tumor cell death, but rather of upregulation of tumor-cell-autonomous type I interferon (IFN) signaling and a strong inflammatory response that resulted in the activation of macrophages and dendritic cells, leading to phagocytosis of tumor cells. Treatment of a MM mouse model with LCL161 established long-term anti-tumor protection and induced regression in a fraction of the mice. Notably, combination of LCL161 with the immune-checkpoint inhibitor anti-PD1 was curative in all of the treated mice.",
author = "Marta Chesi and Mirza, {Noweeda N.} and Garbitt, {Victoria M.} and Sharik, {Meaghen E.} and Amylou Dueck and Yan Asmann and Ilseyar Akhmetzyanova and Kosiorek, {Heidi E.} and Arianna Calcinotto and Riggs, {Daniel L.} and Niamh Keane and Ahmann, {Gregory J.} and Morrison, {Kevin M.} and Rafael Fonseca and Martha Lacy and Dingli, {David M} and Kumar, {Shaji K} and Sikander Ailawadhi and Angela Dispenzieri and Francis Buadi and Morie Gertz and Reeder, {Craig B.} and Yi Lin and {Chanan Khan}, {Asher A} and Stewart, {Alexander Keith} and David Fooksman and Bergsagel, {Peter Leif}",
year = "2016",
month = "12",
day = "1",
doi = "10.1038/nm.4229",
language = "English (US)",
volume = "22",
pages = "1411--1420",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - IAP antagonists induce anti-tumor immunity in multiple myeloma

AU - Chesi, Marta

AU - Mirza, Noweeda N.

AU - Garbitt, Victoria M.

AU - Sharik, Meaghen E.

AU - Dueck, Amylou

AU - Asmann, Yan

AU - Akhmetzyanova, Ilseyar

AU - Kosiorek, Heidi E.

AU - Calcinotto, Arianna

AU - Riggs, Daniel L.

AU - Keane, Niamh

AU - Ahmann, Gregory J.

AU - Morrison, Kevin M.

AU - Fonseca, Rafael

AU - Lacy, Martha

AU - Dingli, David M

AU - Kumar, Shaji K

AU - Ailawadhi, Sikander

AU - Dispenzieri, Angela

AU - Buadi, Francis

AU - Gertz, Morie

AU - Reeder, Craig B.

AU - Lin, Yi

AU - Chanan Khan, Asher A

AU - Stewart, Alexander Keith

AU - Fooksman, David

AU - Bergsagel, Peter Leif

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The cellular inhibitors of apoptosis (cIAP) 1 and 2 are amplified in about 3% of cancers and have been identified in multiple malignancies as being potential therapeutic targets as a result of their role in the evasion of apoptosis. Consequently, small-molecule IAP antagonists, such as LCL161, have entered clinical trials for their ability to induce tumor necrosis factor (TNF)-mediated apoptosis of cancer cells. However, cIAP1 and cIAP2 are recurrently homozygously deleted in multiple myeloma (MM), resulting in constitutive activation of the noncanonical nuclear factor (NF)-ΰ B pathway. To our surprise, we observed robust in vivo anti-myeloma activity of LCL161 in a transgenic myeloma mouse model and in patients with relapsed-refractory MM, where the addition of cyclophosphamide resulted in a median progression-free-survival of 10 months. This effect was not a result of direct induction of tumor cell death, but rather of upregulation of tumor-cell-autonomous type I interferon (IFN) signaling and a strong inflammatory response that resulted in the activation of macrophages and dendritic cells, leading to phagocytosis of tumor cells. Treatment of a MM mouse model with LCL161 established long-term anti-tumor protection and induced regression in a fraction of the mice. Notably, combination of LCL161 with the immune-checkpoint inhibitor anti-PD1 was curative in all of the treated mice.

AB - The cellular inhibitors of apoptosis (cIAP) 1 and 2 are amplified in about 3% of cancers and have been identified in multiple malignancies as being potential therapeutic targets as a result of their role in the evasion of apoptosis. Consequently, small-molecule IAP antagonists, such as LCL161, have entered clinical trials for their ability to induce tumor necrosis factor (TNF)-mediated apoptosis of cancer cells. However, cIAP1 and cIAP2 are recurrently homozygously deleted in multiple myeloma (MM), resulting in constitutive activation of the noncanonical nuclear factor (NF)-ΰ B pathway. To our surprise, we observed robust in vivo anti-myeloma activity of LCL161 in a transgenic myeloma mouse model and in patients with relapsed-refractory MM, where the addition of cyclophosphamide resulted in a median progression-free-survival of 10 months. This effect was not a result of direct induction of tumor cell death, but rather of upregulation of tumor-cell-autonomous type I interferon (IFN) signaling and a strong inflammatory response that resulted in the activation of macrophages and dendritic cells, leading to phagocytosis of tumor cells. Treatment of a MM mouse model with LCL161 established long-term anti-tumor protection and induced regression in a fraction of the mice. Notably, combination of LCL161 with the immune-checkpoint inhibitor anti-PD1 was curative in all of the treated mice.

UR - http://www.scopus.com/inward/record.url?scp=84995470048&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995470048&partnerID=8YFLogxK

U2 - 10.1038/nm.4229

DO - 10.1038/nm.4229

M3 - Article

C2 - 27841872

AN - SCOPUS:84995470048

VL - 22

SP - 1411

EP - 1420

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 12

ER -